Oasmia is developing a new generation of drugs with emphasis on human and veterinary
oncology. Our main business activity focuses on improving product life cycles
and the versatility of current pharmaceuticals. In-house research in nanotechnology
and a long-term working basis can be seen as a guarantee for reaching our highly
In addition to strategic investments in oncology we also have a number of promising
patents and candidates in therapy fields such as infection, asthma and neurology.